(Reuters) - Fitbit Inc (N:FIT) is developing a method to detect irregular heart rhythm in time through a partnership with Bristol-Myers Squibb-Pfizer Alliance, as the wearable device maker looks to match a feature available on rival Apple Inc's (O:AAPL) Watch.
Fitbit has been pushing deeper into the healthcare space and in August tied up with the Singapore government to provide fitness trackers and services in a health program that the company said could reach up to one million users. (https://reut.rs/2TWAkpG)
Under Thursday's deal, the company's devices will carry software that will help detect atrial fibrillation - the most common type of irregular heartbeat - after approval from the U.S. Food and Drug Administration.
Atrial fibrillation is a condition associated with irregular heart rhythm that increases the risk of stroke and is usually prevalent among people above 65 years of age.
About 2.7 million to 6 million people suffer from the condition in the United States, according to the Center of Disease Control and Prevention.